Acasti Pharma

Ticker: ACST

Sector: Pharmaceuticals

Acasti Pharma

Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange. Announces Initiation of Pharmacokinetic Study for GTX-102. Short interest in Acasti Pharma Inc. decreases by 89.7% - defense world. short interest in acasti pharma inc. (nasdaq:acst) Short Interest in Acastsi Pharma. (NASDAQ:ACST) Decreases By 89. 7% Shareholders are encouraged to contact the firm. Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH Patients. WuXi Clinical is a leader in the CRO industry with a strong track record in successfully helping pharmaceutical companies develop innovative therapies, said Prashant Kohli. Prashant Kohli as Acasti Pharmas new Chief Executive Officer, RHEA-AI very positive. Jean-Marie (John) Canan tendered his resignation as Director. Analysts are bullish on top healthcare stocks: acasti pharma (acst), immunoprecise antibodies (ipa) and Evotec AG. H.C. Wainwright analyst Oren Livnat reiterated a Buy rating. Wall Street analysts say Acasti Pharma, Inc.s price is currently Undervalued. The companys upcoming earnings report date is Aug 16, 2023 which is in 31 days. No hedge funds are currently holding shares in DE:A1P0 --- The stock does not have enough of the key information to rate it accurately.